"On the other hand, if it's not excessive bleeding and there are other options to explore, the safety issue may hold you back from doing this."
The treatment did not increase the risk of unwanted clots in veins, regardless of age, the researchers found. It increased the risk of stroke, but not enough to be statistically significant.
Dr. Louis Aledort of the Mount Sinai School of Medicine in New York said in a commentary that 4 percent of the NovoSeven used at his hospital is for non-approved therapy. "At other centers, the rate of off-label use may be even higher," Aledort said.
Levi said hospitals that are quick to give the drug may now want to reconsider that practice.
近期,美国心脏学会(AHA)发布了家族性高胆固醇血症的相关事宜的科学声明,...[详细]
糖尿病与冠心病互为高危因素。当糖尿病与冠心病并存时,患者发生严重不良心血管...[详细]